Form 8-K - Current report:
SEC Accession No. 0000950170-24-094382
Filing Date
2024-08-09
Accepted
2024-08-09 09:06:45
Documents
12
Period of Report
2024-08-07
Items
Item 1.03: Bankruptcy or Receivership
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acor-20240807.htm   iXBRL 8-K 55231
2 EX-99.1 acor-ex99_1.htm EX-99.1 832690
  Complete submission text file 0000950170-24-094382.txt   1115755

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acor-20240807.xsd EX-101.SCH 24851
15 EXTRACTED XBRL INSTANCE DOCUMENT acor-20240807_htm.xml XML 4712
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

EIN.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31938 | Film No.: 241190572
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)